A Study to Assess the Efficacy and Safety of PXT3003 in Charcot-Marie-Tooth Type 1A
Status:
Recruiting
Trial end date:
2023-12-30
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blind, placebo-controlled and multicenter 3 phase trial
evaluating the therapeutic effect and safety of CMT1A by PXT3003. This double-blind study
will assess in parallel groups 1 dose of PXT3003 compared to Placebo in CMT1A patients
treated for 15 months.